✦ LIBER ✦

Evolution of recombinant factor VIII safety: KOGENATE®and Kogenate®FS/Bayer

✍ Scribed by Jeanne M. Lusher; Inge Scharrer

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Virus safety considerations for recombin

✍ DEBRA ARNOLD 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB

Clinical development of recombinant fact

✍ D. HURST 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB

Summary of clinical experience with reco

✍ J. M. Lusher 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 365 KB

Pharmacokinetics of recombinant factor V

✍ C. BARNES; D. LILLICRAP; J. PAZMINO-CANIZARES; V. S. BLANCHETTE; A. M. STAIN; D. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 571 KB

Immune function in patients receiving re

✍ Christine A. Lee 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB

Clinical Evaluation of a Recombinant Fac

✍ A. Yoshioka; K. Fukutake; J. Takamatsu; A. Shirahata; Kogenate Post-Marketing Su 📂 Article 📅 2003 🏛 Carden Jennings Publishing 🌐 English ⚖ 90 KB